Jump to content



  • Please log in to reply
3 replies to this topic

#1 Sneezy12


    Advanced Member

  • Members
  • PipPipPip
  • 67 posts
  • LocationMinnesota

Posted 05 April 2013 - 05:59 AM

http://www.ntkinstit...t_uids=23459450   Frank Also, http://www.ntkinstit...t_uids=23459449

#2 Badger


    New Member

  • Members
  • Pip
  • 0 posts

Posted 05 April 2013 - 11:01 AM

Thanks, but I have enough to worry about.

#3 CDW


    New Member

  • Members
  • Pip
  • 4 posts

Posted 06 April 2013 - 06:50 AM

And without them we'd all be living much shorter lives on Interferon and struggling to get out of bed. useful to know, but there are probably a hundred other things that will kill me before PAOD's effects start to come into play.

#4 Trey


    Advanced Member

  • PS Beta Group
  • PipPipPip
  • 1,705 posts
  • LocationSan Antonio, Texas

Posted 06 April 2013 - 08:46 AM

I don't see the purpose of the articles since they conclude:

"Multivariate logistic regression revealed that nilotinib had no impact on PAOD rates compared with no TKI, whereas imatinib had decreased rates of PAOD compared with no TKI."

So TKIs pose no increased risk of PAD, and even  reduced rates of PAD for Gleevec.  But some researchers think this is a problem anyway?  Proves my theory once again that researchers often write junk just because they have not published anything in a while. 


1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users